Literature DB >> 22009189

Epistatic interactions between thiopurine methyltransferase (TPMT) and inosine triphosphate pyrophosphatase (ITPA) variations determine 6-mercaptopurine toxicity in Indian children with acute lymphoblastic leukemia.

Patchva Dorababu1, Narayana Nagesh, Vijay Gandhi Linga, Sadashivudu Gundeti, Vijay Kumar Kutala, Pallu Reddanna, Raghunadharao Digumarti.   

Abstract

PURPOSE: To explore the role of genetic variants of thiopurine methyltransferase (TPMT) and inosine triphosphate pyrophosphatase (ITPA) in 6-mercaptopurine (6-MP)-induced toxicity in Indian children with acute lymphoblastic leukemia (ALL).
METHODS: Children with ALL receiving 6-MP in maintenance phase of treatment (n = 90) were enrolled in the study. Bidirectional sequencing of TPMT (whole gene) and ITPA (exon 2, exon 3, and intron 2) was undertaken, and correlation between genotype and 6-MP toxicity was assessed.
RESULTS: Five variations were observed in TPMT, including two exonic variations, TPMT*12 (374 C > T) and TPMT*3C (719A > G), and three intronic, intron 3 (12356 C > T), intron 4 (16638 C > T), and TPMT rs2842949. Two exonic, ITPA exon -2 (94 C → A) and exon 3 of ITPA (138 G > A), and one intronic, ITPA intron 2 (A→C), variations were observed in ITPA. Multifactor dimensionality reduction analysis of all the genetic variants showed independent association of ITPA 94 C→A as well as synergic epistatic interactions, i.e., TPMT*12 × ITPA ex3, ITPA ex2 × TPMT*12 × ITPA ex3, and TPMT*3C × ITPA ex2 × TPMT*12 × ITPA ex3, in determining hematological toxicity. This is further substantiated by a multiple linear regression model, which showed moderate predictability of toxicity with these variants (area under the curve = 0.70, p = 0.004).
CONCLUSION: Our results suggest that apart from the individual effect of ITPA 94 C→A, epistatic interactions between the variations of TPMT (*3C, *12) and ITPA (ex2, ex3) are associated with the 6-MP toxicity. Testing these variants facilitates tailoring of the 6-MP therapy in children with ALL.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22009189     DOI: 10.1007/s00228-011-1133-1

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  39 in total

1.  Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus.

Authors:  M V Relling; M L Hancock; G K Rivera; J T Sandlund; R C Ribeiro; E Y Krynetski; C H Pui; W E Evans
Journal:  J Natl Cancer Inst       Date:  1999-12-01       Impact factor: 13.506

2.  Analysis of thiopurine methyltransferase variant alleles in childhood acute lymphoblastic leukaemia.

Authors:  H L McLeod; S Coulthard; A E Thomas; S C Pritchard; D J King; S M Richards; O B Eden; A G Hall; B E Gibson
Journal:  Br J Haematol       Date:  1999-06       Impact factor: 6.998

3.  Thiopurine S-methyltransferase gene polymorphism and 6-mercaptopurine dose intensity in Indian children with acute lymphoblastic leukemia.

Authors:  Gauri Kapoor; Rupal Sinha; Rahul Naithani; Meenal Chandgothia
Journal:  Leuk Res       Date:  2010-02-13       Impact factor: 3.156

4.  Polymorphism of ITPA 94C>A and risk of adverse effects among patients with acute lymphoblastic leukaemia treated with 6-mercaptopurine.

Authors:  W R Wan Rosalina; L K Teh; N Mohamad; A Nasir; R Yusoff; A A Baba; M Z Salleh
Journal:  J Clin Pharm Ther       Date:  2011-05-05       Impact factor: 2.512

5.  Thiopurine S-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians.

Authors:  H L Tai; E Y Krynetski; C R Yates; T Loennechen; M Y Fessing; N F Krynetskaia; W E Evans
Journal:  Am J Hum Genet       Date:  1996-04       Impact factor: 11.025

6.  Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity.

Authors:  R M Weinshilboum; S L Sladek
Journal:  Am J Hum Genet       Date:  1980-09       Impact factor: 11.025

7.  In vitro characterization of four novel non-functional variants of the thiopurine S-methyltransferase.

Authors:  Rima Hamdan-Khalil; Delphine Allorge; Jean-Marc Lo-Guidice; Christelle Cauffiez; Dany Chevalier; Catherine Spire; Nicole Houdret; Christian Libersa; Michel Lhermitte; Jean-Frédéric Colombel; Jean-Luc Gala; Franck Broly
Journal:  Biochem Biophys Res Commun       Date:  2003-10-03       Impact factor: 3.575

8.  Characterization of the inosine triphosphatase (ITPA) gene: haplotype structure, haplotype-phenotype correlation and promoter function.

Authors:  Nicolas von Ahsen; Michael Oellerich; Victor W Armstrong
Journal:  Ther Drug Monit       Date:  2008-02       Impact factor: 3.681

9.  Thiopurine S-methyltransferase alleles, TPMT(*)2, (*)3B and (*)3C, and genotype frequencies in an Indian population.

Authors:  Raju Murugesan; Saadi Abdul Vahab; Satyajit Patra; Rekha Rao; Jyothi Rao; Padmalatha Rai; P M Gopinath; Kapaettu Satyamoorthy
Journal:  Exp Ther Med       Date:  2010-01-01       Impact factor: 2.447

10.  Mercaptopurine metabolism and risk of relapse in childhood lymphoblastic leukaemia.

Authors:  J S Lilleyman; L Lennard
Journal:  Lancet       Date:  1994-05-14       Impact factor: 79.321

View more
  13 in total

1.  Influence of age, sex, and haplotypes of thiopurine methyltransferase (TPMT) gene on 6- mercaptopurine toxicity in children with acute lymphoblastic leukemia.

Authors:  Chakradhara Rao S Uppugunduri; Marc Ansari
Journal:  Eur J Clin Pharmacol       Date:  2011-12-14       Impact factor: 2.953

2.  Prevalence of TPMT polymorphism in Indian patients requiring immunomodulator therapy and its clinical significance.

Authors:  Sandeep Kirit Davavala; Devendra C Desai; Philip Abraham; Tester Ashavaid; Anand Joshi; Tarun Gupta
Journal:  Indian J Gastroenterol       Date:  2013-08-31

Review 3.  Pharmacogenetic determinants of mercaptopurine disposition in children with acute lymphoblastic leukemia.

Authors:  Tiphaine Adam de Beaumais; Evelyne Jacqz-Aigrain
Journal:  Eur J Clin Pharmacol       Date:  2012-03-16       Impact factor: 2.953

Review 4.  Germline oncopharmacogenetics, a promising field in cancer therapy.

Authors:  Chiara Pesenti; Milena Gusella; Silvia M Sirchia; Monica Miozzo
Journal:  Cell Oncol (Dordr)       Date:  2015-01-09       Impact factor: 6.730

5.  2SNP heritability and effects of genetic variants for neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio.

Authors:  Bochao Danae Lin; Elena Carnero-Montoro; Jordana T Bell; Dorret I Boomsma; Eco J de Geus; Rick Jansen; Cornelis Kluft; Massimo Mangino; Brenda Penninx; Tim D Spector; Gonneke Willemsen; Jouke-Jan Hottenga
Journal:  J Hum Genet       Date:  2017-08-03       Impact factor: 3.172

6.  Pharmacogenetic analysis of pediatric patients with acute lymphoblastic leukemia: a possible association between survival rate and ITPA polymorphism.

Authors:  Hyery Kim; Hyoung Jin Kang; Hyo Jeong Kim; Mi Kyung Jang; Nam Hee Kim; Yongtaek Oh; Byoung-Don Han; Ji-Yeob Choi; Chul Woo Kim; Ji Won Lee; Kyung Duk Park; Hee Young Shin; Hyo Seop Ahn
Journal:  PLoS One       Date:  2012-09-24       Impact factor: 3.240

Review 7.  Effect of ITPA Polymorphism on Adverse Drug Reactions of 6-Mercaptopurine in Pediatric Patients with Acute Lymphoblastic Leukemia: A Systematic Review and Meta-Analysis.

Authors:  Yeonhong Lee; Eun Jeong Jang; Ha-Young Yoon; Jeong Yee; Hye-Sun Gwak
Journal:  Pharmaceuticals (Basel)       Date:  2022-03-29

8.  Monitoring thiopurine metabolites in korean pediatric patients with inflammatory bowel disease.

Authors:  Mi Jin Kim; Soo Youn Lee; Yon Ho Choe
Journal:  Yonsei Med J       Date:  2014-09       Impact factor: 2.759

9.  Thiopurine methyltransferase polymorphisms in children with acute lymphoblastic leukemia.

Authors:  Vijay Gandhi Linga; Dorra Babu Patchva; Krishna Mohan Mallavarapu; Venkata Tulasi; Krishnamani Iyer Kalpathi; Ashok Pillai; Sadashivudu Gundeti; Senthil J Rajappa; Raghunadharao Digumarti
Journal:  Indian J Med Paediatr Oncol       Date:  2014-10

10.  Multilocus genotypes of relevance for drug metabolizing enzymes and therapy with thiopurines in patients with acute lymphoblastic leukemia.

Authors:  Gabriele Stocco; Raffaella Franca; Federico Verzegnassi; Margherita Londero; Marco Rabusin; Giuliana Decorti
Journal:  Front Genet       Date:  2013-01-07       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.